The Fridley, Minn.-based company said its bipolar, steroid-eluting SelectSecure leads are designed to be attached to a single or dual chamber pace maker and are now approved for pacing and sensing in the atrium, right ventricle or at the bund of HIS as an alternative to right ventricular placing.
Medtronic said it also offers a C315HIS deliver catheter for placing leads at or near the His bundle.
“There is growing interest among some physicians in His-bundle pacing as an alternative to right ventricular pacing, and we are pleased to offer the SelectSecure MRI lead for those who would like the option of this pacing approach for appropriate patients,” cardiac rhythm and heart failure division chief medical officer Dr. Rob Kowal said in a prepared statement.
Yesterday, Medtronic said it won FDA approval for thoracotomy-based implantation procedures with its HVAD left ventricular assist device, which it said is a less-invasive implantation approach.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.